Pfizer reports final vaccine results: 95% efficacy

An illustration picture shows vials with Covid-19 Vaccine stickers attached, with the logo of US pharmaceutical company Pfizer, on November 17, 2020.

Enlarge / An illustration
picture shows vials with Covid-19 Vaccine stickers attached, with
the logo of US pharmaceutical company Pfizer, on November 17, 2020.
(credit:
Getty JUSTIN TALLIS
)

Pharmaceutical giant Pfizer and German biotech firm BioNTech
announced Wednesday that they have wrapped up the Phase III trial
of their COVID-19 mRNA vaccine, finding it to be
95 percent effective
at preventing disease and consistently
effective across age, gender, race, and ethnicity demographics. The
vaccine appeared effective at preventing cases of severe disease as
well.

The companies added that they have also met a safety
milestone—collecting a median of two months of safety monitoring
data on trial participants—to file a request for an Emergency Use
Authorization (EUA) with the US Food and Drug Administration. They
plan to file the request “within days.”

“The study results mark an important step in this historic
eight-month journey to bring forward a vaccine capable of helping
to end this devastating pandemic,” Dr. Albert Bourla, Pfizer
Chairman and CEO, said in a statement. “We continue to move at
the speed of science to compile all the data collected thus far and
share with regulators around the world.”

Read 9 remaining
paragraphs

Source: FS – All – Science – News
Pfizer reports final vaccine results: 95% efficacy